reports
Victory Capital Reports Strong First-Quarter Results
SAN ANTONIO, Texas--(BUSINESS WIRE)-- Victory Capital Holdings, Inc. (NASDAQ: VCTR) (“Victory Capital” or “the Company”) today reported financial results for the quarter ended March 31, 2024. “We achieved very strong results to start 2024,” said David Brown, Chairman and Chief Executive Officer. “During the first quarter, our long-term gross and net flows improved quarter-over-quarter and year-over-year, reaching their best levels in more than a year. This momentum accelerated toward the end of the quarter, with our long-term net flows turning positive in March. Additionally, we posted the h...
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Resul...
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results CANTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31st, 2024. First Quarter 2024 Financial Results Summary: Net revenue of $110.0 million for the first quarter of 2024, an increase of $2.3 million compared to net revenu...
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and...
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for t...
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to En...
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients. MARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of lab...
Lantronix to Participate in the 19th Annual Needham Technology, Media,...
Lantronix to Participate in the 19th Annual Needham Technology, Media, & Consumer Investor Conference on May 14, 2024 IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: LTRX), a global provider of compute and connectivity IoT solutions, today announced that Lantronix CFO Jeremy Whitaker will participate in a fireside chat on Tuesday, May 14, 2024, at 11:45 a.m. Eastern Time and one-on-one meetings with investors at the 19th Annual Needham Technology, Media, & Consumer Investor Conference at the Westin Grand Central Hotel in New York City. The live audio webcast and replay of the ...
Vintage Wine Announces Forbearance Agreement Extension with Lenders
SANTA ROSA, Calif.--(BUSINESS WIRE)-- (Nasdaq: VWE and VWEWW) (the “Company”) today announced that the Company and its lender group have amended the amended and restated forbearance agreement dated April 2, 2024 (as amended, the “amended forbearance agreement”) to extend the forbearance period to June 4, 2024. The lenders have also agreed to defer the $10 million principal payment previously due at May 15, 2024 to June 17, 2024. Under the amendment to the amended and restated forbearance agreement, the lender group has agreed to not exercise any rights and remedies until June 4, 2024, so lo...
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics to Present at Upcoming Investor Conferences NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences. The presentation details are as follows: RBC Capital Markets 2024 Global Healthcare Conference, on Tuesday, May 14, at 1:35 p.m. Eastern Time. Dr. Tabuteau will participate in ...
VPG Reports Fiscal 2024 First Quarter Results
VPG Reports Fiscal 2024 First Quarter Results MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, today announced its results for its 2024 first fiscal quarter ended March 30, 2024. First Fiscal Quarter Highlights: Revenues of $80.8 million decreased 9.1% from a year ago.Gross profit margin was 43.4%, as compared to 41.9% reported a year ago.Operating margin was 8.6%, as compared to 11.2% reported a year ago.Adjusted operating margin* was 10.0%, as compared to 11.4% reported a year a...
- Jonathan Moreland
SAIA SAIA INC.
RYI RYERSON HOLDING CORPORATION
LTRX LANTRONIX INC.
HXL HEXCEL CORPORATION
HOO HERBALIFE NUTRITION LTD.
AIN ALBANY INTERNATIONAL CORP. CLASS A
HWBK HAWTHORN BANCSHARES
HI HILLENBRAND INC.
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
EAF GRAFTECH INTERNATIONAL
GH GUARDANT HEALTH
DNA GINKGO BIOWORKS HOLDINGS
TBBK INC.
RXO_w THE BANCORP
VSTS_w INC.
CFFI RXO INC
RENT VESTIS CORPORATION
C&F FINANCIAL CORPORATION
RENT THE RUNWAY INC
Lantronix Inc: 3 directors
Three Directors at Lantronix Inc bought 51,000 shares at between 3.590USD and 3.660USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...
Akoya Biosciences Opens Operations and Manufacturing Center of Excelle...
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company’s PhenoCycler®-Fusion and the PhenoImager® HT platforms. “Spatial biology is transforming drug discovery, translational sciences, and clinical research, and advancing our ability to un...
Axsome Therapeutics Reports First Quarter 2024 Financial Results and P...
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2024 net product revenue of $21.6 million representing 64% year-over-year growth Contract executed with second large group purchasing organization (GPO) for potential coverage of Auvelity Positive pivotal Phase 3 trial results of AXS-12 in narcolepsy announced Topline results of ADVANCE-2 Phase 3 tr...
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulator...
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows KR-HT5 is based on Akoya’s PhenoImager® HT Platform MARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT...
Moody's Ratings places Victory Capital's ratings on review for possibl...
Moody's Ratings (Moody's) has placed the Ba2 corporate family rating and senior secured debt rating of Victory Capital Holdings, Inc. (Victory) on review for possible upgrade as well as the company's Ba2-PD probability of default rating. Previously, the outlook was stable. The rating action follow...
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
Axsome Therapeutics Recognizes May as Mental Health Awareness Month NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today is joining the global community of mental health advocates, including Mental Health America, during May’s Mental Health Month to raise awareness of the importance of mental health as a key element of overall health. Axsome is committed to the millions of individuals living with mental health conditions...
Lantronix Reports Record Revenue for Third Quarter of Fiscal 2024
Lantronix Reports Record Revenue for Third Quarter of Fiscal 2024 Third Quarter Net Revenue of $41.2 Million, up 11 Percent Sequentially and up 25 Percent Year-Over-YearThird Quarter GAAP EPS of ($0.01) vs. ($0.08) in the Prior Year Third Quarter Non-GAAP EPS of $0.11 vs. $0.06 in the Prior Year IRVINE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: LTRX), a global provider of compute and connectivity IoT solutions, today reported results for its third quarter of fiscal 2024. Net revenue totaled $41.2 million, up 11 percent sequentially and up 25 percent year-over-year. ...
Lantronix to Report Fiscal 2024 Third Quarter Results on April 29, 202...
Lantronix to Report Fiscal 2024 Third Quarter Results on April 29, 2024 IRVINE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: LTRX), a global provider of compute and connectivity IoT solutions, today announced it will release financial results from its fiscal 2024 third quarter ended March 31, 2024, after the close of the market on Monday, April 29, 2024. Management will host an investor conference call and audio webcast at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on April 29, 2024. To access the live conference call, investors should dial 1-844-802-2442...
Employers Holdings, Inc. Reports First Quarter 2024 Results and Increa...
Employers Holdings, Inc. Reports First Quarter 2024 Results and Increases Regular Quarterly Dividend to $0.30 per Share Company to Host Conference Call on Friday, April 26, 2024, at 11:00 a.m. Eastern Daylight Time HENDERSON, Nev., April 25, 2024 (GLOBE NEWSWIRE) -- Employers Holdings, Inc. (the “Company”) (NYSE:EIG), a holding company with subsidiaries that are specialty providers of workers' compensation insurance and services focused on small and select businesses engaged in low-to-medium hazard industries, today reported financial results for its first quarter ended March 31, 2024. ...
Home BancShares, Inc. Announces Second Quarter Cash Dividend
Home BancShares, Inc. Announces Second Quarter Cash Dividend CONWAY, Ark., April 24, 2024 (GLOBE NEWSWIRE) -- Home BancShares, Inc. (NYSE: HOMB), parent company of Centennial Bank, today announced that its Board of Directors has declared a regular $0.18 per share quarterly cash dividend payable June 5, 2024, to shareholders of record May 15, 2024. This cash dividend is consistent with the quarterly dividends paid during 2023. Home BancShares, Inc. is a bank holding company, headquartered in Conway, Arkansas. Its wholly-owned subsidiary, Centennial Bank, provides a broad range of commerci...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.